GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes

Expert Opinion on Investigational Drugs

Volumn 23, Issue 10, 2014, Pages 1441-1448

  Cariou, Bertrand ^a,b,c   Staels, Bart ^b,d,e,f,g  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b L INSTITUT DU THORAX   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e UNIV LILLE   (France)

^f France   (France)

^g Clinique d'Endocrinologie Hotel Dieu CHU de Nantes   (France)

Author keywords

Dyslipidemia; Insulin resistance; Nonalcoholic steatohepatitis; PPAR ; PPAR

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; GFT 505; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPENYL)PHENOXYL)-2-METHYLPROPANOIC ACID; CHALCONE DERIVATIVE; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROPIONIC ACID DERIVATIVE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; DRUG SAFETY; DYSLIPIDEMIA; FLUID RETENTION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; HUMAN; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FUNCTION; METABOLIC DISORDER; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PHASE 2 CLINICAL TRIAL (TOPIC); PUBLICATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; AGONISTS; ANIMAL; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; DYSLIPIDEMIAS; LIPID METABOLISM; METABOLISM; MOUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY;

ANIMALS; CHALCONES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; GLUCOSE; HUMANS; LIPID METABOLISM; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR ALPHA; PPAR DELTA; PROPIONATES;

EID: 84907056944     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.954034     Document Type: Article

References (52)

1. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes : a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
3. Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French Population-Based Study. PLoS One 2012;7(3):e32412
4. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925-9
5. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806
6. Smith BW, Adams LA. Nonalcholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7:456-65
7. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. Hepatology 2012;55:2005-23
8. Ratziu V, Bellentani S, Cortez-Pinto S, et al. A position statement on NAFLD/ NASH based on the EASL special conference. J Hepatol 2010;53:372-84
9. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-8
10. Postic C, Girard J. Contribution of de novo acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829-38
11. Zhan Y, An W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol 2010;16:4652-60
12. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-15
13. Phielix E, Szendroedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci 2011;32:607-16
14. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (London) 2012;122:253-70
15. Juurinen L, Kotronen A, Graner M, et al. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab 2008;93:118-24
16. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91
17. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of piogliotazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-22307
18. Boettcher E, Csako G, Pucino F, et al. Meta-analysis : pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012;35:66-75
19. Colca JR, McDonald WG, Kletzien RF. Mitochondrial target of thiazolidinediones. Diabetes Obes Metab 2014. [Epub ahead of print]
20. Colca JR, VanderLugt JT, Adams WJ, et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOTmodulating insulin sensitizing. Clin Pharmacol Ther 2013;93:352-9
21. Intercept Pharmaceuticals, Inc. Press release. 2014. Available from: http://ir. interceptpharma.com/releasedetail.cfm? ReleaseID=818725
22. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy andsafety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574-82
23. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 2010;30:894-9
24. Lefebvre P, Chinetti G, Fruchart JC, et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-80
25. Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferatoractivated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003;100:15924-9
26. Lee CH, Olson P, Hevener A, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006;103:3444-9
27. Sprecher DL, Massien C, Pearce G, et al. Triglyceride: high density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007;27:359-65
28. Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferatoractivated receptor (PPAR) delta promotes reversal of multiple metabolic abnormalities reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57:332-9
29. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferatoractivated receptor alpha/ delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013;36:2923-30
30. Lalloyer F, Wouters K, Baron M, et al. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol 2011;31:1573-9
31. Staels B, Rubenstrunk A, Noël B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis. Hepatology 2013;58:1941-52
32. Hanf R, Millatt L, Cariou B, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gammaassociated cardiac adverse events. Diab Vasc Dis Res 2014;In press
33. Stienstra R, Mandard S, Patsouris D, et al. Peroxisome proliferator-activated receptor alpha protects against obesityinduced hepatic inflammation. Endocrinology 2007;148:2753-63
34. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 2012;1821:809-18
35. Iwaisako K, Haimerl M, Paik YH, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proc Natl Acad Sci USA 2012;109:E1369-76
36. Cariou B, Zär Y, Staels B, et al. Effects of the new dual PPAR alpha/ delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011;34:2008-14
37. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-7
38. Stefan N, Häring HU. The roles of hepatokines in metabolism. Nat Rev Endocrinol 2013;9:144-52
39. Liu S, Brown JD, Stanya KJ, et al. A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature 2013;502:550-4
40. Genfit. Press release. 2014. Available from: http://www.genfit.com/ wp-content/uploads/2014/06/2014-06-27-PR-GENFIT-DSMB.pdf
41. Genfit. Press release. 2014. Available from: http://www.genfit.com/wp-content/ uploads/2014/03/2012.02.08- PR-GENFIT-EN.pdf
42. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008;5:542-5
43. Fievet C, Fruchart JC, Staels B. PPAR alpha and PPAR gamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006;6:606-14
44. Lincoff AM, Tardiff JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus:the AleCardio randomized clinical trial. JAMA 2014;311:1515-12
45. Ting RD, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment : the FIELD study. Diabetes Care 2012;35:218-25
46. Udanis SM, Bakris GL. Do fibrates truly preserve kidney function Nat Rev Endocrinol 2011;7:130-1
47. Mackenzie LS, Lione L. Harnessing the benefits of PPAR beta//delta agonists. Life Sci 2013;93:963-7
48. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010;95:829-36
49. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with non alcoholic fatty liver disease. J Clin Endocrinol Metab 2010;95:829-36
50. Bajaj M, Suraamornkul S, Hardies LJ, et al. Effects of peroxisome proliferatoractivated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007;50:1723-31
51. Chen Y, Hu Y, Lin M, et al. Therapeutic effects of PPAR alpha agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 2013;62:261-72
52. ACCORD study group, ACCORD Eye study group. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44